>
Switch to:

Altamira Therapeutics ROA %

: -60.06% (As of Jun. 2021)
View and export this data going back to 2014. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Altamira Therapeutics's annualized Net Income for the quarter that ended in Jun. 2021 was $-14.88 Mil. Altamira Therapeutics's average Total Assets over the quarter that ended in Jun. 2021 was $24.78 Mil. Therefore, Altamira Therapeutics's annualized ROA % for the quarter that ended in Jun. 2021 was -60.06%.

The historical rank and industry rank for Altamira Therapeutics's ROA % or its related term are showing as below:

NAS:CYTO' s ROA % Range Over the Past 10 Years
Min: -416.03   Med: -69.77   Max: -41.26
Current: -70.84

-416.03
-41.26

During the past 10 years, Altamira Therapeutics's highest ROA % was -41.26%. The lowest was -416.03%. And the median was -69.77%.

NAS:CYTO's ROA % is ranked lower than
99.99% of the 327 Companies
in the Biotechnology industry.

( Industry Median: -49.25 vs. NAS:CYTO: -70.84 )

Altamira Therapeutics ROA % Historical Data

The historical data trend for Altamira Therapeutics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROA %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.32 -93.25 -82.73 -69.77 -56.28

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
ROA % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.83 -57.97 -62.95 -78.51 -60.06

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics ROA % Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's ROA % distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's ROA % falls into.



Altamira Therapeutics ROA % Calculation

Altamira Therapeutics's annualized ROA % for the fiscal year that ended in Dec. 2020 is calculated as:

ROA %=Net Income (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=-9.2300765420982/( (9.3893751272135+23.411751463305)/ 2 )
=-9.2300765420982/16.400563295259
=-56.28 %

Altamira Therapeutics's annualized ROA % for the quarter that ended in Jun. 2021 is calculated as:

ROA %=Net Income (Q: Jun. 2021 )/( (Total Assets (Q: Dec. 2020 )+Total Assets (Q: Jun. 2021 ))/ count )
=-14.882132628332/( (23.411751463305+26.145626790042)/ 2 )
=-14.882132628332/24.778689126673
=-60.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2021) net income data. ROA % is displayed in the 30-year financial page.


Altamira Therapeutics  (NAS:CYTO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2021 )
=Net Income/Total Assets
=-14.882132628332/24.778689126673
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-14.882132628332 / 0)*(0 / 24.778689126673)
=Net Margin %*Asset Turnover
=N/A %*0
=-60.06 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2021) net income data. The Revenue data used here is two times the semi-annual (Jun. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Altamira Therapeutics ROA % Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)